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A B S T R A C T
Atherosclerosis and its complications are responsible for one in three global deaths. Nutraceuticals show promise
in the prevention and treatment of atherosclerosis but require an indepth understanding of the mechanisms
underlying their actions. A previous study showed that the omega-6 fatty acid, dihomo-γ-linolenic acid (DGLA),
attenuated atherosclerosis in the apolipoprotein E deﬁcient mouse model system. However, the mechanisms
underlying such protective eﬀects of DGLA are poorly understood and were therefore investigated. We show that
DGLA attenuates chemokine-driven monocytic migration together with foam cell formation and the expression
of key pro-atherogenic genes induced by three pro-inﬂammatory cytokines in human macrophages. The eﬀect of
DGLA on interferon-γ signaling was mediated via inhibition of signal transducer and activator of transcription-1
phosphorylation on serine 727. In relation to anti-foam cell action, DGLA inhibits modiﬁed LDL uptake by both
macropinocytosis and receptor-mediated endocytosis, the latter by reduction in expression of two key scavenger
receptors (SR-A and CD36), and stimulates cholesterol eﬄux from foam cells. DGLA also improves macrophage
mitochondrial bioenergetic proﬁle by decreasing proton leak. Gamma-linolenic acid and prostaglandin E1,
upstream precursor and key metabolite respectively of DGLA, also acted in an anti-atherogenic manner. The
actions of DGLA extended to other key atherosclerosis-associated cell types with attenuation of endothelial cell
proliferation and migration of smooth muscle cells in response to platelet-derived growth factor. This study
provides novel insights into the molecular mechanisms underlying the anti-atherogenic actions of DGLA and
supports further assessments on its protective eﬀects on plaque regression in vivo and in human trials.
1. Introduction
Atherosclerosis, an inﬂammatory disease of the vasculature and the
underlying cause of cardiovascular disease (CVD), is responsible for
about 31.5% of all global deaths [1–3]. The disease represents a major
healthcare and economic burden and this may worsen in the future
because of global increases in risk factors such as diabetes and obesity
[1,2]. Atherosclerosis is initiated in response to various risk factors,
particularly the accumulation of LDL in the intima of arteries and its
subsequent oxidation to oxidized LDL (oxLDL) [1–3]. This then triggers
arterial endothelial cell activation and/or dysfunction leading to se-
cretion of chemokines by these cells and increased expression of
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adhesion proteins on their cell surface [1–3]. Immune cells, particularly
monocytes, are recruited to the site of oxLDL accumulation [1–3].
These monocytes diﬀerentiate into macrophages that then take up
oxLDL by various processes, including scavenger receptor (SR)-medi-
ated endocytosis and macropinocytosis, that together with defective
cholesterol eﬄux from these cells results in the formation of lipid-laden
foam cells [3,4]. As the disease progresses, foam cells lyse by apoptosis
and necrosis leading to the formation of a lipid-rich necrotic core as-
sociated with a chronic inﬂammatory response orchestrated by cyto-
kines such as interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α)
and interleukin (IL)-1β [5,6]. Smooth muscle cells proliferate and mi-
grate from the media to the intima to stabilize the plaques by the
production of an extracellular matrix (ECM) that forms part of the ﬁ-
brous cap of atherosclerotic lesions [2–5]. The stability of such plaques
is dictated in part by the synthesis and degradation of the ECM [2–5].
Excessive degradation by a range of proteases produced under in-
ﬂammatory conditions causes plaque destabilization and ultimately
rupture and subsequent thrombosis [2–5].
Statins have had signiﬁcant impact in the recent reduction of CVD
morbidity and mortality in developed countries [2,7]. However, many
clinical trials have highlighted the considerable residual risk of CVD in
patients on statin therapy together with issues such as tolerability and
patient-dependent eﬃcacy [2,7]. Emerging pharmaceutical therapies
such as ezetimibe, which inhibits the dietary absorption of cholesterol,
monoclonal antibodies or small interfering RNA that target the protease
proprotein convertase subtilisin/kexin type 9 involved in the degrada-
tion of the LDL receptor, and monoclonal antibodies against IL-1β have
shown some promise though many of these are expensive [2]. Un-
fortunately, the recent clinical outcomes on numerous pharmaceutical
agents against established targets (e.g. inhibitors of cholesteryl ester
transfer protein, acyl-coenzyme A acyltransferase 1 and lipoprotein-
associated phospholipase A2) have been disappointing [2,8]. Nu-
traceuticals (food products with health beneﬁts beyond their nutritional
value) represent promising agents for the prevention of atherosclerosis
and as add-on with current therapies but require an in-depth under-
standing of their beneﬁcial eﬀects together with the underlying me-
chanisms of their actions in vitro and in vivo [2,3].
Polyunsaturated fatty acids (PUFAs) have many health beneﬁts and
previous research on omega-3 PUFAs has demonstrated several anti-
atherogenic actions [1,2,9]. Some omega-6 PUFAs also have health
beneﬁts that are poorly understood because of a general paucity of
research performed on them in comparison to omega-3 PUFAs or many
other nutraceuticals [1,2,9]. Further studies on beneﬁcial omega-6
PUFAs are required to inform on their use as preventative and ther-
apeutic agents and because of issues of sustainability and environment
associated with the use of omega-3-rich ﬁsh oils [9]. DGLA is an im-
portant omega-6 PUFA that is well tolerated with no side eﬀects in
studies on animal model systems and in humans [10–12]. Limited
studies have shown association of low levels of DGLA with ischemic
heart disease and severity of coronary artery disease together with risk
factors such as insulin resistance, non-insulin dependent diabetes mel-
litus and metabolic syndrome [13–15]. In contrast, DGLA levels are
higher in Eskimos who have low prevalence of coronary artery disease
[16]. DGLA also reversed hypertension in rats by diets rich in saturated
fats [17], decreased cutaneous inﬂammatory responses in mice pro-
duced by croton oil [18] and demonstrated antithrombotic potential in
humans [19]. In addition, studies on apolipoprotein E deﬁcient mice
(ApoE−/−) fed a normal chow diet supplemented with DGLA for
6months showed reduced lipid deposition in the aorta together with
the content of macrophages and smooth muscle cells and the expression
of adhesion molecules intercellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) [20]. Furthermore, in
ApoE−/− mice fed a Paigen diet for 1month, DGLA decreased areas of
lipid accumulation in the aorta together with the expression of adhesion
proteins [20]. Although providing evidence for an anti-atherogenic role
of DGLA, this study was rather restrictive in terms of mechanistic
insight and provided no indications on the eﬀects of DGLA on several
key cellular processes associated with atherosclerosis. We have there-
fore investigated this key aspect with particular focus on macrophages,
a key cell type involved in all the diﬀerent stages of the disease [21].
The studies were also extended to some key atherosclerosis-associated
processes in endothelial cells and vascular smooth muscle cells (VSMC).
2. Materials and methods
2.1. Reagents
Human THP-1 cell line, human umbilical cord endothelial cells
(HUVEC) and human aortic smooth muscle cells (HASMC) together
with murine RAW264.7 cell line were from Sigma-Aldrich. The other
reagents were from: Abcam [lactate dehydrogenase (LDH) kit]; Cell
Signaling Technology [anti phospho-STAT1 Tyr701 (91675), anti
phospho-STAT1 Ser727 (91775)]; GE Healthcare (14C-cholesterol); Nu-
Chek Prep, Inc. (DGLA); Cayman Chemical [prostaglandin E1 (PGE1)
and gamma-linolenic acid (GLA)]; Nycomed Pharmaceuticals
(Lymphoprep™); Peprotech [monocyte chemotactic protein-1 (MCP-1),
IL-1β, IFN-γ, TNF-α]; Perkin-Elmer (1-14C-acetate); VWR Lifescience
(Ribozol™); Santa Cruz Biotechnology Inc. [anti-STAT1 (Sc-592), anti-
β-actin (Sc-130656), anti-SR-A (Sc-20660)] or Intracel [1,1′-diocta-
decyl-3,3,3′,3′-tetramethyllindocarbocyane perchlorate (DiI)-labeled
oxLDL (DiI-oxLDL) and acetylated LDL (AcLDL)].
2.2. Cell culture
Primary human monocyte-derived macrophages (HMDM) were
isolated from monocytes obtained from buﬀy coats (National Blood
Service Wales) using Ficoll-Hypaque puriﬁcation as previously de-
scribed [22–25]. Ethical approval and informed consent for each donor
was granted by the Welsh Blood Service for use of human blood sam-
ples. The investigation conforms to the principles outlined in the De-
claration of Helsinki. Human THP-1 cell line, mouse RAW264.7 cell line
and HMDM were cultured in RPMI1640 medium with stable glutamine
supplemented with 10% (v/v) heat-inactivated foetal calf serum (HI-
FCS), penicillin (100 U/ml) and streptomycin (100 μg/ml) at 37°C in a
humidiﬁed atmosphere containing 5% (v/v) CO2. THP-1 monocytes
were diﬀerentiated into macrophages by incubation for 24 h with
0.16 μM of phorbol 12-myristate 13-acetate (PMA) [6,22–25]. HUVEC
and HASMC were cultured in their appropriate ready to use media
according to the manufacturer's instructions (Sigma-Aldrich). Cell via-
bility and proliferation assays were carried out as our previous study
[23].
2.3. Real-time quantitative PCR (RT-qPCR)
RNA isolation, reverse transcription and RT-qPCR analysis of re-
sulting cDNA were performed as described elsewhere [6,22,23]. The
sequences of the primers are given in Supplementary Table 1. The
comparative ΔΔCt method was used to represent relative expression
normalized to the levels of the house-keeping gene [6,23].
2.4. Western blotting
Equal amounts of proteins were size-fractionated by SDS-PAGE
alongside comparative molecular weight size markers to determine the
size of the protein product and subjected to Western blot analysis as
described elsewhere [6,22,24,25].
2.5. Migration assays
Monocyte migration in response to the chemokine MCP-1 was car-
ried out as our previous study [23]. Migration of HASMC (1×105 cells)
was performed using a modiﬁed Boyden chamber with 8 μm porous
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insert coated with Matrigel [26] (E6909; Sigma-Aldrich). HASMC in-
cubated with vehicle or DGLA for the requisite time in serum-free
DMEM were in the upper chamber whereas the lower chamber con-
tained 20 ng/ml platelet-derived growth factor (PDGF)-BB as a che-
moattractant. After 4 h at 37°C in a humidiﬁed incubator with 5% (v/v)
CO2, the inserts were carefully cut out using a scalpel and the cells on
the underside of the membrane stained with Fluoroshield™ with DAPI
mounting medium (F6057; Sigma-Aldrich). The membranes were vi-
sualised using ﬂuorescent microscopy and the total number of cells in
ﬁve diﬀerent ﬁelds counted.
2.6. Analysis of parameters related to foam cell formation
Cells (2× 106) were pre-treated for 24 h with vehicle or DGLA in
RPMI supplemented with 0.2% (v/v) fatty acid free BSA and then in-
cubated in the absence or the presence of 50 μg/ml AcLDL and 1 μCi of
[1-14C]-acetate for a further 24 h. The cells were scraped, pelleted by
centrifugation at 9000×g and resuspended in 1ml of distilled water.
An aliquot was removed for protein analysis using a Micro BCA™
Protein assay Kit in accordance to the manufacturer's instructions
(Thermo Fisher Scientiﬁc). To 1ml of lysed cell suspension, 2ml of
chloroform: methanol (1:2, v/v) solution was added, mixed thoroughly
and incubated for 15min at room temperature. Then, 1ml of chloro-
form and 2ml of Garbus solution (2M KCl in 0.5M potassium phos-
phate buﬀer pH 7.6) [27] were added, mixed and centrifuged at 220×g
for 3min at room temperature. The chloroform layer containing the
extracted lipids was dried in a stream of nitrogen, dissolved in 50 μl
chloroform and used for the separation of polar lipids (PL) and non-
polar lipids, including triacylglycerols (TAG), non-esteriﬁed fatty acids
(NEFA), free cholesterol (FC) and cholesteryl esters (CE), by one di-
mension thin layer chromatography (TLC) on silica gel G plates
(10×10 cm; Merk KGaA) using hexane: diethyl ether: acetic acid
Fig. 1. DGLA attenuates IFN-γ induced MCP-1 and ICAM-1 expression in human and mouse macrophages.
THP-1 macrophages (A–B), primary HMDM (C–D) or mouse RAW264.7 macrophages (E–F) were pre-incubated for 24 h with the indicated concentrations of DGLA
(A–B) or 50 μM DGLA (+, C–F) or DMSO vehicle (−). The cells were then incubated for 3 h with 250 U/ml IFN-γ (+) or its vehicle (−). Total RNA was subjected to
RT-qPCR using primers against MCP-1 (A, C, E), ICAM-1 (B, D, F) or the housekeeping genes [human GAPDH (A–D) or mouse β-actin (E–F)]. The mRNA levels were
calculated using the comparative Ct method and normalized to the housekeeping gene with values from cells pre-incubated with DMSO vehicle and then treated with
IFN-γ given an arbitrary value of 1. Graphs display normalized gene expression (mean ± SEM) from three independent experiments. Statistical analysis was
performed using a One-way ANOVA (equal variances) with Tukey's post hoc analysis (*, p≤ 0.05; ***, p≤ 0.001).
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(80:20:1, v/v/v) solvent mixture. Radioactivity in the various lipid
classes was determined by scintillation counting. Dil-oxLDL uptake,
lucifer yellow (LY) uptake and cholesterol eﬄux assays were carried out
as our previous studies [22,24,25,28].
2.7. Determination of PGE1 levels in cell supernatants
Hexane: isopropanol: 1M acetic acid (30:20:2, v/v/v) was added to
media collected from 4×106 cells in a ratio of 2.5ml of solvent mix-
ture to 1ml of media. An internal standard containing 10 ng PGE1-d4
was also included. Samples were mixed thoroughly by vortexing and
2.5 ml hexane was added followed by further vortexing. The samples
were subjected to centrifugation (900×g for 5min at room tempera-
ture) and the upper hexane layer transferred into a new glass tube. The
hexane extraction was repeated again as above followed by evaporation
of the samples under a stream of nitrogen and reconstitution in 200 μl
of 100% HPLC grade methanol. The extracted lipids were then sepa-
rated on a Spherisorb C18 ODS2, 5 μm, 150mm×4.6mm column
(Waters Ltd) using a gradient of 20–90% mobile phase B (A: water:
acetonitrile: acetic acid, 75:25:0.1, v/v/v; B: methanol: acetonitrile:
acetic acid, 60:40:0.1, v/v/v) over 60min with a ﬂow rate of 1ml/min.
PGE1 was quantiﬁed by LC-MS/MS electrospray ionization on a Q-Trap
(Applied Biosystems 4000 Q-Trap) with speciﬁc multiple reaction
monitoring (MRM) transitions (M−H−; PGE1: 353.2/273.2, PGE1-d4:
357.2/277.2) monitored as parent fragmenting to daughter with colli-
sions energies of−20 to−28 V (MS conditions were DP−65, CE−30,
dwell time 150ms).
2.8. Determination of mitochondrial bioenergetic proﬁle
This was determined using XFe96 Seahorse analyzer and XF cell
mito stress test kit (mitochondrial respiration) together with XF-
FluxPaks containing 96-well plates and cartridges (Agilent
Technologies). Oligomycin (ATP synthase blocker), carbonyl cyanide-4-
(triﬂuoromethoxy)phenylhydrazone (FCCP; mitochondrial uncoupler)
and a mixture of rotenone (inhibitor of complex I) and antimycin-A
(blocker of complex III) in the kit were serially injected to determine
ATP-linked respiration, maximal respiration and non-mitrochondrial
respiration respectively. These parameters together with basal respira-
tion were then used to determine proton leak, spare respiratory capa-
city and coupling eﬃciency. Optimization experiments with diﬀerent
cell numbers and titration of various inhibitors were ﬁrst carried out to
assess various parameters as previous studies [29,30]. These were
found to be 200,000 cells per well of a Seahorse plate, 1 μM oligomycin,
2 μM of FCCP and 0.15 μM rotenone/antimycin-A mix. A non-cell blank
was included in all experiments. The experiments and data analysis
were performed as described by the manufacturer (Agilent Technolo-
gies).
2.9. Statistical analysis
Data are presented as mean ± SEM on assigned number of in-
dependent experiments. Normality of data was tested using the Shapiro-
Wilk test and single comparisons were performed using an unpaired
Student's t-test. A One-way ANOVA with Tukey's post hoc analysis or
Kruskal-Wallis test with Dunn's post hoc test were used when more than
two groups were compared. The results were regarded as signiﬁcant
when p≤ 0.05.
3. Results
3.1. DGLA attenuates pro-inﬂammatory gene expression in human and
mouse macrophages
Previous studies showed that DGLA at concentrations of 50–200 μM
inhibited lipopolysaccharide (LPS) induced TNF-α production in per-
ipheral blood mononuclear cells (PBMC) [31]. To investigate whether
such anti-inﬂammatory action extends to macrophages and other pro-
inﬂammatory/atherogenic mediators, the eﬀect of several concentra-
tions of DGLA on IFN-γ induced expression of MCP-1 and ICAM-1
mRNA, which are both expressed at high levels during inﬂammation
and atherosclerosis [5,23], was ﬁrst investigated in human THP-1
macrophages. IFN-γ is a key pro-atherogenic cytokine and potentially
one of the master regulator of the disease [32]. The human THP-1 cell
line is used widely for studies of human monocytes/macrophages in
atherosclerosis with demonstrated conservation of responses to primary
cultures and in vivo [22–25,33,34]. As expected, the expression of both
MCP-1 and ICAM-1 was signiﬁcantly induced by IFN-γ (p < 0.001 in
both cases; Fig. 1A–B). DGLA at concentrations of 25 μM, 50 μM and
100 μM produced signiﬁcant inhibition of the IFN-γ-induced MCP-1
expression (p= 0.012, p < 0.001 and p < 0.001 respectively;
Fig. 1A). For ICAM-1 a signiﬁcant inhibition of IFN-γ-induced
Fig. 2. DGLA attenuates IFN-γ induced phosphorylation of STAT1 on serine
727.
THP-1 macrophages were pre-treated with 50 μM DGLA (+) or DMSO vehicle
(−) for 24 h. The cells were then stimulated for 30min [24] with 250 U/ml
IFN-γ (+) or its vehicle (−). Equal amount of proteins were subjected to
Western blot analysis with antibodies against phospho-STAT1 Tyr701, phospho-
STAT1 Ser727 or total STAT1. The data were subjected to densitometric and
statistical analysis. A representative image is shown in (A) with graphs in-
dicating the relative phosphorylation (mean ± SEM) on tyrosine701 (B) or
serine727 (C) from three independent experiments. The values from cells treated
with vehicle alone have been arbitrarily assigned as 1. Statistical analysis was
performed using a One-way ANOVA with Tukey's post hoc analysis (*,
p≤ 0.05; ***, p≤ 0.001).
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expression was seen with 50 μM and 100 μM DGLA (p=0.050 and
p=0.038 respectively; Fig. 1B). Given the signiﬁcant inhibition of IFN-
γ-induced expression of two key pro-inﬂammatory genes by 50 μM
DGLA, this concentration was used for subsequent studies unless or
otherwise stated. Indeed, this concentration had no eﬀect on the via-
bility of cells, as judged by the release of the LDH enzyme, or their
proliferation, as gauged by staining with crystal violet, both in the
absence or the presence of IFN-γ stimulation (Supplementary Fig. 1). In
addition, the use of 50 μM and 100 μM DGLA showed that the fatty acid
was indeed taken up by the cells and incorporated into total polar lipid
and triacylglycerol fractions (see C20:3n6 in Supplementary Fig. 2).
To rule out the possibility that the DGLA-mediated inhibition of
IFN-γ induced MCP-1 and ICAM-1 expression was peculiar to the THP-1
cell line, comparative analysis was performed in primary HMDM. DGLA
attenuates IFN-γ induced expression of MCP-1 and ICAM-1 in HMDM
(p < 0.001 and p=0.051 respectively; Fig. 1C–D). DGLA also inhibits
the IFN-γ induced expression of MCP-1 and ICAM-1 in murine
RAW264.7 macrophages (p= 0.022 and p= 0.045 respectively;
Fig. 1E–F), thereby demonstrating conservation of response between
human and mouse macrophages.
Signal transducer and activator of transcription-1 (STAT-1) is a key
transcription factor in IFN-γ signaling and involved in the inducible
expression of the MCP-1 and ICAM-1 genes [24,32,33]. Binding of IFN-γ
to its cell surface receptors initiates Janus kinase-mediated phosphor-
ylation of tyrosine 701, which triggers its dimerization, translocation to
the nucleus and activation of gene transcription [24]. In addition,
phosphorylation of serine 727 is required for maximal activity [24]. To
evaluate whether the DGLA-mediated inhibition of IFN-γ induced MCP-
1 and ICAM-1 expression involved modulation of phosphorylation at
these two sites, Western blot analysis was performed using phospho-
speciﬁc antibodies. Fig. 2 shows that DGLA inhibits the IFN-γ induced
phosphorylation of STAT1 on serine 727 (p= 0.012) without aﬀecting
that on tyrosine 701.
To rule out the possibility that the inhibitory action of DGLA was
restricted to IFN-γ, its eﬀect on the induced expression of MCP-1 and
ICAM-1 by two other key pro-atherogenic cytokines, IL-1β and TNF-α
[5] was determined. Fig. 3 shows that DGLA attenuates the induction of
MCP-1 and ICAM-1 expression by both IL-1β (p < 0.001 and
p=0.001 respectively) and TNF-α (p < 0.001 in both cases).
Cholesterol crystal-mediated inﬂammasome activation and IL-1β
production is also involved in chronic inﬂammation during athero-
sclerosis [5]. However, consistent with a previous study on mouse
macrophages [35], DGLA had no eﬀect on cholesterol crystal-mediated
secretion of IL-1β in human macrophages (data not shown). ROS pro-
duction is also associated with inﬂammation and oxidation of LDL [3].
The eﬀect of DGLA on tert-butyl hydroperoxide (TBHP)-induced ROS
production in both monocytes and macrophages was therefore in-
vestigated. Supplementary Fig. 3 shows that DGLA had no eﬀect on ROS
levels produced by TBHP in both monocytes and macrophages. In ad-
dition, mitochondrial ROS production was not aﬀected by DGLA
(Supplementary Fig. 4).
3.2. DGLA attenuates chemokine-driven monocytic migration and
macrophage foam cell formation
Studies in ApoE−/− mice showed reduced macrophage burden in
aortic lesions following DGLA feeding [20]. This could potentially be
because of reduced chemokine-driven recruitment of monocytes. To
investigate this potential mechanism, the eﬀect of DGLA on monocyte
migration induced by the key chemokine, MCP-1, was determined.
DGLA inhibits MCP-1 driven migration of monocytes (p=0.005;
Fig. 4A).
Macrophage foam cell formation is dependent on the uptake of
modiﬁed LDL and the eﬄux of cholesterol from foam cells [4]. The
scavenger receptor-mediated uptake of modiﬁed LDL is important in
foam cell formation [4]. DGLA signiﬁcantly attenuates the uptake of
Dil-labeled oxLDL (p=0.003; Fig. 4B). Macropinocytosis is another
process involved in the uptake of lipoproteins that contributes to foam
Fig. 3. DGLA attenuates IL-1β and TNF-α induced MCP-1 and ICAM-1 expression in human macrophages.
THP-1 macrophages were pre-incubated for 24 h with 50 μM DGLA (+) or DMSO vehicle (−). The cells were then treated for 24 h with 1000 U/ml of IL-1β or TNF-α
as indicated (+) or its vehicle (−). Total RNA was subjected to RT-qPCR using primers against MCP-1 (A, C), ICAM-1 (B, D) or GAPDH. The mRNA levels were
calculated using the comparative Ct method and normalized to the housekeeping gene with values from cells pre-incubated with DMSO vehicle and then treated with
the cytokine given an arbitrary value of 1. Graphs display normalized gene expression (mean ± SEM) from three independent experiments. Statistical analysis was
performed using a One-way ANOVA (equal variances) with Tukey's post hoc analysis (*, p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001).
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cell formation [4,28]. DGLA also attenuates macropinocytosis as judged
by the uptake of the dye lucifer yellow (LY) [28] (p < 0.001; Fig. 4C).
The eﬀect of DGLA on cholesterol eﬄux was also monitored by ﬁrst
converting macrophages into foam cells using AcLDL, which is avidly
taken up by the cells [22,24,25], in the presence of [14C]-cholesterol.
The eﬄux of radiolabeled cholesterol to ApoAI acceptor present in HDL
particles was then determined [23,25]. DGLA stimulates the eﬄux of
cholesterol from foam cells (p= 0.008; Fig. 4D).
Foam cell formation is associated with increased intracellular levels
of cholesteryl esters [4,25]. We therefore investigated the eﬀect of
DGLA on the incorporation of [1-14C]-acetate into various lipid classes
(polar lipids, free cholesterol, non esteriﬁed fatty acids, triacylglycerols
and cholesteryl esters) following incubation with AcLDL by TLC and
scintillation counting. RAW264.7 macrophages were used for these
studies because initial experiments showed that they accumulate higher
levels of cholesteryl esters than THP-1 macrophages (data not shown).
Preliminary optimization experiments showed that treatment with
100 μM DGLA for 24 h was optimal for analysis of changes in choles-
teryl esters levels (data not shown) so these were used for subsequent
studies. Fig. 4E shows that the cellular cholesteryl ester content was
Fig. 4. DGLA inhibits MCP-1 driven monocytic migration and macrophage foam cell formation.
(A) Migration assays were carried out with THP-1 monocytes incubated for 3 h with 50 μM DGLA (+) or vehicle (−) using MCP-1 (+, 20 ng/ml) as a chemoat-
tractant. Cells incubated with vehicle in the absence MCP-1 were also included for comparative purposes. Monocyte migration was calculated by counting the
number of cells that had migrated across a cell insert and expressed as a percentage of total input cells. Graph displays percentage migration (mean ± SEM) from
three independent experiments, with values from cells incubated with vehicle and MCP-1 arbitrarily assigned as 100%. (B) THP-1 macrophages were incubated with
50 μM DGLA (+) or vehicle (−) for 24 h and then with Dil-oxLDL (+) for a further 24 h. Cells treated with vehicle in the absence of Dil-oxLDL were also included for
comparative purposes. The Dil-oxLDL uptake in cells incubated with vehicle and Dil-oxLDL has been arbitrarily assigned as 100%. The graph indicates the uptake
(mean ± SEM) from four independent experiments. (C) THP-1 macrophages were incubated with 50 μM DGLA (+) or vehicle (−) for 24 h and then with LY for a
further 24 h. LY uptake in cells incubated with vehicle has been arbitrarily assigned as 100%. The graph indicates the LY uptake (mean ± SEM) from three
independent experiments. (D) THP-1 macrophages were pre-treated with 50 μM DGLA (+) or vehicle (−) for 24 h and then incubated for 24 h in the presence of
25 μg/ml AcLDL and 0.5 μCi [14C]-cholesterol in RPMI media containing 0.2% (w/v) BSA. Cells were then incubated with 10 μg/ml ApoAI for 24 h. Background
cholesterol eﬄux (in the absence of ApoA1, not displayed on graph) was subtracted from those incubated with ApoA1. The graph shows percentage cholesterol eﬄux
(mean ± SEM) from three independent experiments. (E) RAW264.7 macrophages were pre-treated with 100 μM DGLA or vehicle for 24 h prior to the addition of
50 μM AcLDL and 1 μCi [1-14C] acetate for a further 24 h. Cells incubated with vehicle but in the absence of AcLDL were also included for comparative purposes.
Lipids were extracted, separated by TLC and radioactive incorporation into individual lipid classes was determined by scintillation counting. Graph shows percentage
incorporation of [1-14C]-acetate per mg of protein into polar lipids (PL), free cholesterol (FC), non esteriﬁed fatty acids (NEFA), triacylglycerols (TAG) and cholesteryl
esters (CE). Statistical analysis was performed using either a One-way ANOVA with Tukey's post hoc analysis (A, B, E) or an unpaired Student's t-test (C, D) (*,
p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001).
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signiﬁcantly increased with AcLDL (p= 0.010) and this was attenuated
by DGLA (p= 0.032), thereby conﬁrming inhibition of foam cell for-
mation by this fatty acid.
Uncontrolled uptake of modiﬁed LDL by SRs is crucial in macro-
phage foam cell formation [4]. The eﬀect of DGLA on the expression of
SR-A and CD36, which play crucial roles in modiﬁed LDL uptake [4,25],
was therefore determined. DGLA attenuates the expression of both
these scavenger receptors at the mRNA level (p= 0.047 and p= 0.012
respectively; Fig. 5A–B). To evaluate whether such changes in mRNA
expression were followed at the protein level, Western blot analysis was
carried out for SR-A. DGLA signiﬁcantly attenuates SR-A expression
(p= 0.019; Fig. 5C). The cell surface expression of SR-A, CD36 and LDL
receptor (LDLR) was also determined by ﬂow cytometry and found to
be attenuated by DGLA (Supplementary Fig. 5).
3.3. DGLA modulates mitochondrial respiration
Mitochondrial dysfunction has been associated with atherosclerosis
[36]. The eﬀect of DGLA at concentration of 50 μM, which has no eﬀect
on cell viability or proliferation (see Supplementary Fig. 1), on the
bioenergetic proﬁle of THP-1 macrophages was therefore determined
using the Seahorse XFe96 analyzer. Fig. 6 shows that DGLA produces
signiﬁcant, favourable changes in respiration parameters, including
reduction in proton leak (p < 0.001) and increase in non mitochon-
drial respiration (p=0.026), spare respiratory capacity (p= 0.026)
and coupling eﬃciency (p=0.039). No signiﬁcant changes were seen
for basal respiration, ATP-linked respiration and maximal respiration
(Fig. 6). Similarly, DGLA produced no signiﬁcant changes in various
parameters related to glycolysis (Supplementary Fig. 6).
3.4. GLA is also anti-atherogenic
It would be expected that GLA, an upstream precursor of DGLA,
would also be anti-atherogenic. Representative experiments were
therefore performed to investigate this possibility. GLA attenuates IFN-γ
induced MCP-1 and ICAM-1 expression at concentrations of
25 μM–100 μM (as used for our previous studies on DGLA shown in
Fig. 1A–B) with signiﬁcant inhibition seen with 100 μM GLA (p= 0.007
and p=0.011 respectively; Fig. 7A–B). The use of this concentration of
GLA also showed inhibition of MCP-1 driven monocytic migration
(p < 0.001; Fig. 7C).
3.5. PGE1, a key metabolite of DGLA, has similar anti-atherogenic actions
DGLA can be metabolized to PGE1 via the cyclooxygenase pathway
and increased levels of this eicosanoid have been seen following
treatment of mouse peritoneal macrophages with GLA [37] and human
mononuclear leukocytes with DGLA [38]. In order to conﬁrm that PGE1
levels were indeed increased following stimulation of THP-1 macro-
phages with DGLA, its concentration in cell supernatants was de-
termined under non-inﬂammatory and inﬂammatory conditions, the
latter involving stimulation of the cells with the pro-inﬂammatory cy-
tokine IFN-γ as in the studies shown in Figs. 1–2. Thus, the cells were
pre-treated for 24 h with the DMSO vehicle or 100 μM DGLA followed
by a further 24 h incubation with IFN-γ (250 U/ml) or its vehicle. As
shown in Fig. 8A, there was a signiﬁcant increase in PGE1 levels fol-
lowing pre-treatment of the cells with DGLA both cases (p= 0.024 in
the absence of IFN-γ and p=0.006 in the presence of the cytoki-
ne).This suggests that the actions of DGLA could potentially be medi-
ated via PGE1, which would therefore also be expected to have anti-
atherogenic actions. In order to investigate this possibility, the eﬀect of
several concentrations of PGE1, as our studies on DGLA (Fig. 1A–B) and
GLA (Fig. 7A–B), on IFN-γ induced MCP-1 and ICAM-1 expression in
THP-1 macrophages was therefore analyzed. A shorter pre-incubation
time of 1 h with PGE1 was chosen compared to DGLA because of the
short half-life of this prostaglandin [39]. Pre-treatment of the cells with
all the concentrations of PGE1 signiﬁcantly attenuates the IFN-γ in-
duced expression of both MCP-1 and ICAM-1 genes (Fig. 8B; for MCP-1,
p=0.001 for 10 μM PGE1 and p < 0.001 for all the other con-
centrations and for ICAM-1, p=0.030 for 10 μM PGE1, p=0.002 for
25 μM PGE1, p= 0.011 for 50 μM PGE1 and p= 0.004 for 100 μM
PGE1). The lowest concentration of PGE1 (10 μM) was used for the
analysis of its eﬀects on chemokine driven monocyte migration. Similar
to DGLA, PGE1 also signiﬁcantly attenuates MCP-1 induced monocytic
Fig. 5. DGLA attenuates the expression of SR-A and CD36 in human macro-
phages.
THP-1 macrophages were pre-incubated for 24 h with 50 μM DGLA (+) or
vehicle (−). (A-B) Total RNA was subjected to RT-qPCR using primers against
SR-A (A), CD36 (B) or GAPDH. The mRNA levels were calculated using the
comparative Ct method and normalized to the housekeeping gene with values
from cells treated with vehicle given an arbitrary value of 1. Graphs display
normalized gene expression (mean ± SEM) from four independent experi-
ments. (C) Equal amount of proteins were subjected to Western blot analysis
with antibodies against SR-A and β-actin. The data were subjected to densito-
metric and statistical analysis. A representative image is shown on top with
graph indicating the relative SR-A expression (mean ± SEM) from four in-
dependent experiments. The value from cells treated with vehicle alone has
been arbitrarily assigned as 1. In all cases, statistical analysis was performed
using an unpaired Student's t-test (*, p≤ 0.05).
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Fig. 6. DGLA modulates the bioenergetic proﬁle of human macrophages.
THP-1 macrophages were treated with 50 μM DGLA (+) or vehicle (−) for 24 h. Parameters of mitochondrial respiration were analyzed using the Seahorse XFe96
analyzer. Readouts included: Basal respiration (A); ATP-linked respiration (B); proton leak (C); non mitochondrial respiration (D); maximal respiration (E); spare
respiratory capacity (F) and coupling eﬃciency (G). Graphs represent mean ± SEM from three independent experiments. Statistical analysis was carried out using an
unpaired Student's t-test (*, p≤ 0.05; ***, p≤ 0.001). A trace from a representative experiment carried out in triplicate is shown in panel H.
H. Gallagher, et al. BBA - Molecular Basis of Disease 1865 (2019) 2538–2550
2545
migration (Fig. 8C; p= 0.015).
3.6. The action of DGLA extends to endothelial cells and VSMC
The eﬀect of DGLA on proliferation of HUVEC was determined be-
cause endothelial cell proliferation plays an important role in athero-
sclerosis [40]. Fig. 9A–B shows that DGLA signiﬁcantly attenuates
proliferation of these cells (p= 0.001) without aﬀecting their viability.
In contrast, similar to macrophages (Supplementary Fig. 3), the TBHP-
induced production of ROS was not aﬀected in HUVEC (Supplementary
Fig. 7).
The eﬀect of DGLA on VSMC was also investigated because previous
in vivo studies in ApoE−/− mice showed reduced α-smooth muscle cell
actin-positive area to the intimal area following feeding of DGLA [20].
DGLA at 50 μM had no eﬀect on the viability of HASMC (data not
shown). However, the proliferation of these cells over a 7-day-period
was increased by DGLA (Fig. 9C). In contrast, their migration in re-
sponse to the growth factor PDGF-BB was signiﬁcantly attenuated
(p= 0.031; Fig. 9D) and could account for reduced numbers of smooth
muscle cells seen in vivo [20].
4. Discussion
Omega-6 PUFAs are generally considered pro-atherogenic because
of their ability to produce pro-inﬂammatory lipids and antagonize the
actions of omega-3 PUFAs [1,2,9]. However, not all omega-6 PUFAs are
pro-atherogenic and previous studies in ApoE−/− mice showed that
DGLA supplementation reduced plaque burden and lipid content in the
aorta together with levels of macrophages and smooth muscle cells, and
the expression of ICAM-1 and VCAM-1 [20]. However, the molecular
mechanisms responsible for such beneﬁcial changes are poorly under-
stood and were therefore addressed in this study. DGLA attenuates
MCP-1 and ICAM-1 expression in macrophages induced by three key
pro-atherogenic cytokines, IFN-γ, IL-1β and TNF-α [5] (Figs. 1 and 3).
For IFN-γ, the cytokine-mediated phosphorylation of STAT1 on serine
727 was attenuated by the fatty acid (Fig. 2). DGLA also attenuates
MCP-1 driven migration of monocytes (Fig. 4A), a potential mechanism
for reduced content of monocytes/macrophages seen in studies on
ApoE−/− mice in vivo [20]. Consistent with reduced plaque lipid con-
tent in vivo [20], DGLA inhibits macrophage foam cell formation via
reduced uptake of modiﬁed LDL, due to decreased expression of key
scavenger receptors, and macropinocytosis together with increased
cholesterol eﬄux from foam cells (Figs. 4–5). DGLA also produced fa-
vourable changes in mitochondrial bioenergetic proﬁle, particularly
signiﬁcant reduction in proton leak (Fig. 6) often associated with mi-
tochondrial dysfunction [41]. GLA, an upstream precursor of DGLA,
also attenuates IFN-γ-induced MCP-1 and ICAM-1 expression and che-
mokine-driven monocytic migration (Fig. 7). PGE1, whose levels in-
crease markedly following pre-treatment of the cells with DGLA, also
attenuates the IFN-γ induced expression of MCP-1 and ICAM-1 together
with chemokine driven monocytic migration (Fig. 8). The action of
DGLA was not restricted to macrophages but extended to endothelial
cells and VSMC (Fig. 9). Thus, the DGLA-mediated inhibition of VSMC
migration (Fig. 9D) provides a potential mechanism for a decrease in
these cells in ApoE−/− mice in vivo [20]. These studies also reveal
potential cell type speciﬁc mechanisms for DGLA actions (e.g. inhibi-
tion of endothelial cell proliferation whereas stimulation of this in the
case of VSMC; Fig. 9). The mechanisms underlying such diﬀerential
actions of DGLA remains to be determined. Overall, taken together, the
studies presented here provide novel insights into the molecular me-
chanisms underlying the anti-atherogenic actions of DGLA.
Inﬂammation in atherosclerosis is orchestrated by cytokines and
IFN-γ, IL-1β and TNF-α represent three major pro-atherogenic cyto-
kines [5]. In addition, the importance of IL-1β and the potential of
targeting inﬂammation were revealed by the positive outcome of the
CANTOS trial using canakinumab, a therapeutic monoclonal antibody
Fig. 7. GLA attenuates macrophage pro-inﬂammatory gene expression and
chemokine-driven monocytic migration.
(A–B), THP-1 macrophages were pre-incubated for 24 h with the indicated
concentration of GLA or DMSO vehicle (−). The cells were then incubated for
3 h with 250 U/ml IFN-γ (+) or its vehicle (−). Total RNA was subjected to RT-
qPCR using primers against MCP-1 (A), ICAM-1 (B) or GAPDH. The mRNA le-
vels were calculated using the comparative Ct method and normalized to the
housekeeping gene with values from cells pre-incubated with vehicle and then
treated with IFN-γ given an arbitrary value of 1. Graphs display normalized
gene expression (mean ± SEM) from three independent experiments. (C),
migration assays were carried out with THP-1 monocytes incubated for 3 h with
50 μM GLA (+) or vehicle (−) using MCP-1 (20 ng/ml) as the chemoattractant.
Cells incubated with vehicle in the absence MCP-1 were also included for
comparative purposes. Monocyte migration was calculated by counting the
number of cells that had migrated across a cell insert and expressed as a per-
centage of total input cells. Graph displays percentage migration
(mean ± SEM) from three independent experiments, with MCP-1-driven mi-
gration in the presence of vehicle arbitrarily assigned as 100%. In all cases,
statistical analysis was performed using a One-way ANOVA with Tukey's post
hoc analysis (*, p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001).
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targeting this cytokine [2]. DGLA attenuates the expression of MCP-1
and ICAM-1 induced by three cytokines (Figs. 1 and 3) and this re-
presents a potential mechanism for reduced expression of ICAM-1 (and
VCAM-1) in ApoE−/− in vivo [20]. Such anti-inﬂammatory action may
potentially extend to other inﬂammatory disorders. Thus, reduced
production of MCP-1 was also seen in inﬂamed mouse ear produced by
croton oil application following oral administration of DGLA-producing
Saccharomyces cerevisiae [18]. In addition, individuals with arthritis
have higher incidence of atherosclerosis and DGLA attenuated IL-1β
stimulated proliferation of human adherent synovial cells [42], a hall
mark of rheumatoid arthritis. DGLA also attenuated LPS-induced gen-
eration of TNF-α in PBMC [31] so the anti-inﬂammatory actions of this
fatty acid extend to the production of cytokines. The CANTOS trial
revealed higher incidence of fatal infections [2] so dampening in-
ﬂammation by multiple cytokines using nutraceuticals such as DGLA
might be a safer option than drastic reduction of the action of cytokine
(s) via the use of monoclonal antibodies or soluble decoy receptors.
STAT1 is a key transcription factor in IFN-γ signaling [24,32] and is
also required for optimal foam cell formation and atherosclerotic lesion
development in vivo [43]. DGLA inhibits IFN-γ-induced
Fig. 8. PGE1, a key metabolite of DGLA, inhibits macrophage pro-inﬂammatory gene expression and chemokine-driven monocytic migration.
(A), THP-1 macrophages were pre-incubated for 24 h with 100 μM DGLA (+) or vehicle (−) followed by a further 24 h stimulation with 250 U/ml IFN-γ (+) or its
vehicle (−). Media was collected and lipids extracted for measurement using HPLC-MS. Graphs display concentration of PGE1 (ng/ml from 4×106 cells) from three
independent experiments (mean ± SEM). (B), THP-1 macrophages were pre-incubated for 1 h with the indicated concentration of PGE1 (+) or DMSO vehicle (−).
The cells were then treated for 3 h with 250 U/ml IFN-γ (+) or its vehicle (−). Total RNA was subjected to RT-qPCR using primers against MCP-1, ICAM-1 or GAPDH.
The mRNA levels were calculated using the comparative Ct method and normalized to the housekeeping gene with values from cells pre-incubated with vehicle and
then treated with IFN-γ given an arbitrary value of 1. Graphs display normalized gene expression (mean ± SEM) from three independent experiments. (C), migration
assays were carried out with THP-1 monocytes incubated for 3 h with 10 μM PGE1 (+) or vehicle (−) using MCP-1 (20 ng/ml) as the chemoattractant. Cells
incubated with vehicle in the absence MCP-1 were also included for comparative purposes. Monocyte migration was calculated by counting the number of cells that
had migrated across a cell insert and expressed as a percentage of total input cells. Graph displays percentage migration (mean ± SEM), with MCP-1-driven
migration in the presence of vehicle arbitrarily assigned as 100%. Statistical analysis was performed using a Kruskal-Wallis test with Dunn's post hoc test (A) or a One-
way ANOVA with Tukey's post hoc analysis (B–C) (*, p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001).
H. Gallagher, et al. BBA - Molecular Basis of Disease 1865 (2019) 2538–2550
2547
phosphorylation of STAT1 on serine 727 but not tyrosine 701 (Fig. 2), a
potential mechanism for attenuation of MCP-1 and ICAM-1 expression
induced by this cytokine (Fig. 1). Phosphorylation of STAT1 on serine
727 is required for maximal activity and knock-in mice where this
amino acid has been substituted by alanine show reduced expression of
IFN-γ induced gene expression in macrophages [32]. In addition, at-
tenuation of STAT1 serine 727 phosphorylation by inhibition of up-
stream kinases in human macrophages decreased the IFN-γ-induced
expression of several genes, including MCP-1 and ICAM-1, together
with the uptake of modiﬁed lipoproteins [24]. This inhibition of IFN-γ-
induced STAT1 serine 727 phosphorylation potentially represents a key
anti-atherogenic action of DGLA because this cytokine is known to
regulate about 30% of the macrophage transcriptome [32]. In addition
to IFN-γ, STAT1 has been implicated as a point of convergence and
integration for other pro-inﬂammatory signaling pathways resulting in
increased smooth muscle cell and leukocyte activation and migration
[44]. Indeed, reduced atherosclerotic lesion size and progression in
diabetic mice following blockade of tumour necrosis factor-like weak
inducer of apoptosis (TWEAK/Tnfsf12) was mediated through sup-
pression of STAT1 signaling [45]. It is therefore possible that the DGLA-
mediated inhibition of IL-1β- and TNF-α-induced gene expression could
also be mediated via STAT1 though other transcription factors such as
nuclear factor-κB [3] may also be involved.
Omega-3 PUFAs appear to have some similar anti-atherogenic ac-
tions as DGLA reported here. For example, our previous studies have
shown that eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) inhibited MCP-1-driven monocytic migration [23] and macro-
pinocytosis [46]. However, some diﬀerences in the mechanisms of ac-
tion have also been identiﬁed. Thus, EPA and DHA, but not DGLA, at-
tenuated inﬂammasome activation [35]. In addition, DGLA attenuated
the expression of SR-A and CD36 (Fig. 5) whereas this was not seen
with EPA and DHA [46].
Foam cell formation, a critical early event in atherosclerosis [4], is a
complex process involving chemokine-driven recruitment of monocytes
and their diﬀerentiation to macrophages, production of ROS leading to
the oxidation of LDL, uptake of such oxLDL by macrophages, and the
eﬄux of cholesterol from foam cells to acceptors such as HDL or its key
apolipoprotein ApoA1 and subsequent reverse cholesterol transport [4].
Although DGLA had no eﬀect on ROS production (Supplementary
Figs. 3 and 7), the fatty acid attenuates chemokine-driven monocytic
migration together with the uptake of modiﬁed LDL by both SR-medi-
ated endocytosis and macropinocytosis, and stimulates cholesterol ef-
ﬂux from foam cells (Fig. 4). Such an anti-foam activity is likely to be a
major contributor to the anti-atherogenic actions of DGLA and poten-
tially responsible for the reduced plaque lipid content in ApoE mice in
vivo [20]. SR-A and CD36 are two key SRs in the receptor-mediated
uptake of modiﬁed LDL [3,4] and DGLA attenuates the expression of
both these SRs (Fig. 5 and Supplementary Fig. 5), potentially a key
mechanism for its anti-foam cell action.
The mechanisms underlying the induction of macrophage choles-
terol eﬄux by DGLA remains to be determined. ATP-binding cassette
transporter (ABC)-A1 and -G1 are key mediators of macrophage cho-
lesterol eﬄux to lipid free ApoA1 and HDL respectively and ApoE also
contributes to the process [4]. Preliminary experiments showed that
DGLA did not increase the expression of ABCA1 and ABCG1 mRNA
together with the ABCA1 and ApoE proteins in foam cells (data not
shown). ABCA1, ABCG1 and ApoE are regulated by liver X receptors
(LXRs) [47]. However, RT-qPCR showed that rather than inducing,
DGLA signiﬁcantly inhibited LXR-α and -β mRNA expression in THP-1
macrophages (Supplementary Fig. 8). Interestingly, inhibition of LXR
Fig. 9. DGLA modulates the properties of endothelial cells and VSMC.
(A–B), HUVEC were incubated with 50 μM DGLA (+) or vehicle (−) for 24 h. Media were removed and used to determine LDH release. The remaining cells were then
used in the crystal violet assay. Both graphs display fold-change of absorbance values (mean ± SEM) in comparison to vehicle control (arbitrarily assigned as 1) from
three independent experiments. (C), The proliferation of HASMC treated with vehicle or 50 μM DGLA over 7 days was carried out by consecutive crystal violet assays
between days 0 and 7. Each day had its own vehicle control (arbitrarily assigned as 1) and proliferation was determined relative to this. (D), HASMC migration was
carried out as described in Materials and methods. The results are expressed as fold change of migrated cells determined in ﬁve ﬁelds of view in relation to the vehicle
control (−; arbitrarily assigned as 1). Graphs show mean ± SEM from three independent experiments. In all cases, statistical analysis was carried out using an
unpaired Student's t-test (*, p≤ 0.05; **, p≤ 0.01 ***, p≤ 0.001). For C, similar outcome was obtained by regression analysis.
H. Gallagher, et al. BBA - Molecular Basis of Disease 1865 (2019) 2538–2550
2548
actions by other beneﬁcial PUFAs such as EPA and linoleic acid (LA)
have also been previously demonstrated [48–50]. This suggests me-
chanisms independent of the LXR/ABCA1/ABCG1/ApoE axis in the
promotion of cholesterol eﬄux by DGLA, similar to some other PUFAs
[51,52]. For example, LA stimulated cholesterol eﬄux in human mac-
rophages and this was associated with increased expression of Cell
death-inducing DFF45 like eﬀector and Perilipin-Adipophilin-TIP47
family members [51]. In addition, stimulation of cholesterol eﬄux by
α-linolenic acid was associated with decreased expression of stearoyl
CoA desaturase 1, a rate limiting enzyme in the synthesis of mono-
unsaturated fatty acids [52].
5. Conclusion
This is the ﬁrst study that provides detailed mechanistic insight into
the anti-atherogenic action of DGLA previously seen in a limited study
on ApoE deﬁcient mice in vivo [20]. DGLA attenuated several pro-
atherogenic processes: pro-inﬂammatory gene expression by three key
cytokines; chemokine-driven monocytic migration; foam cell formation;
and VSMC migration. The anti-inﬂammatory action of DGLA on IFN-γ
signaling was via modulation of STAT1 serine 727 phosphorylation.
DGLA inhibited foam cell formation by reducing the uptake of modiﬁed
LDL by macropinocytosis and by decreasing the expression of two key
SRs, SR-A and CD36, and stimulated cholesterol eﬄux from foam cells.
DGLA also attenuated proliferation of endothelial cells, and improved
mitrochondrial function (i.e. reduced proton leak). These studies
highlight the potential of DGLA in the prevention and treatment of
atherosclerosis. Future studies should investigate the eﬃcacy of DGLA
to cause regression of existing atherosclerotic plaques in mouse model
systems, and to reduce CVD burden and associated risk factors in
clinical trials.
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